ImmuCell Financials - Benzinga

ImmuCell Corp

ICCCNASDAQ

Trade with Public

Trade with Public

$10.07

0.080.8%

Last update: Sep 23, 12:20 PM

Overview News Earnings Forecast EventsFinancialsSentiment Ownership Compare Stock Report

ImmuCell Financials

ImmuCell (ICCC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY

ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186 million in sales

Benzinga Newsdesk

PRO
ImmuCell Q2 Total Product Sales Rises 12%

ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,

Benzinga Newsdesk

PRO
ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY

ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.21 per share. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.357 million in sales this

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY

ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.31) per share. This is a 616.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $7.626 million in sales this

Benzinga Newsdesk

Earnings Scheduled For March 4, 2026

Benzinga Insights